Strategies of Tumor Immune Evasion

@article{Seliger2012StrategiesOT,
  title={Strategies of Tumor Immune Evasion},
  author={Barbara Seliger},
  journal={BioDrugs},
  year={2012},
  volume={19},
  pages={347-354}
}
During the last decade, increased understanding of the molecular mechanisms responsible for immune activation to protect against challenges by tumor cells has revolutionized the field of immunotherapy research. It has been demonstrated that the dysfunction of the host’s immune system represents one of the major mechanisms by which tumors evade immunosurveillance. This is due, for example, to T cell anergy, the existence of regulatory T cells, and systemic defects of dendritic cells derived from… Expand
Tumor Associated Immune Dysfunction: Immune Cells Involved and Suggested Therapies
TLDR
The role of immune cells that support tumor growth are discussed and some immunotherapeutic strategies that may increase tumor immunogenicity and improve immunotherapy are suggested. Expand
Immunomodulation and Genomic Instability
TLDR
The focus of this chapter is the influence of genomic instability on the pro- and anti-tumor immune activities that impact on cancer development at multiple stages of progression. Expand
Adaptive Immunity Does Not Strongly Suppress Spontaneous Tumors in a Sleeping Beauty Model of Cancer
TLDR
Results indicate that B and T cells function to shape the genetic profile of tumors in various tumor types, despite being ineffective at clearing SB-induced tumors. Expand
Cancer vaccine development: designing tumor cells for greater immunogenicity.
TLDR
These immunotherapies are discussed as well as a feasible and efficient alternative that, in pre-clinical animal models, allows for the expression of specific immunostimulatory molecules on the surface of tumor cells by a novel protein transfer technology. Expand
Innate Immunity Protein Tag7 Induces 3 Distinct Populations of Cytotoxic Cells That Use Different Mechanisms to Exhibit Their Antitumor Activity on Human Leukocyte Antigen-Deficient Cancer Cells
TLDR
The treatment of human peripheral blood lymphocytes with the innate immunity protein Tag7 induces differentiation of the populations of NK (natural killer) cells and CD8+ and CD4+ T lymphocytes that are cytotoxic for human leukocyte antigen-negative tumor cells. Expand
DNA Vaccination: Using the Patient's Immune System to Overcome Cancer
TLDR
Using the patient's own immune system by activation of humoral and cellular immune responses to target the cancer cells has shown first promising results in clinical trials and may allow reduced toxicity standard therapy regimen in the future. Expand
Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies
TLDR
Oncolytic viruses have the added benefit of being directly cytolytic to cancer cells and thus promote antigen recognition within a highly immune-stimulating tumour microenvironment, which complicates their use upon previous exposure. Expand
Canine Parvovirus and Its Non-Structural Gene 1 as Oncolytic Agents: Mechanism of Action and Induction of Anti-Tumor Immune Response
TLDR
The oncolytic properties of Canine Parvovirus (CPV or CPV2), the structure of the NS1 protein, the mechanism of on colytic action as well as role in inducing an antitumor immune response in different tumor models are discussed. Expand
The role of regulatory T lymphocytes in immune control of MC-2 fibrosarcoma
TLDR
It is found that splenocytes of both control and Treg depleted tumor bearing mice strongly but differently inhibited growth of tumor cells in vitro, and upon i.v. injecting specific monoclonal anti-Treg antibodies immediately prior to tumor cell intracutaneous transplantation, the tumor was rejected after initial growth. Expand
Oncolytic Virus Immunotherapy in Sarcoma
TLDR
Several trials are currently accruing patients with histologically confirmed soft-tissue and bone sarcoma studying use of oncolytic viruses alone and in combination with chemotherapy, radiation therapy, and immunotherapy, offering much promise for the future. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 143 REFERENCES
Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance.
  • M. Mapara, M. Sykes
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
Approaches to exploiting this beneficial effect without the deleterious consequence of graft-versus-host disease in allogeneic hematopoietic cell recipients are discussed. Expand
Tumor-induced immune dysfunction
TLDR
The underlying causes of tumor-associated immune suppression of CTL and NK cell activity are discussed, and features of interest shared with HIV infection, leprosy, and rheumatoid arthritis are also be mentioned. Expand
Tumors as elusive targets of T-cell-based active immunotherapy.
TLDR
Current knowledge of the different 'levels' of immune response that might be necessary for immunotherapy to be effective in the treatment of cancer are reviewed and the mechanism(s) governing tumor rejection by the immune system in response to TA-specific immunization is discussed. Expand
Effective immunotherapy against cancer
  • K. Malmberg
  • Medicine
  • Cancer Immunology, Immunotherapy
  • 2004
TLDR
A review discusses some of the salient issues that still need to be resolved in immunotherapy, focusing on the role of oxidative stress and the use of antioxidants to alleviate the immune hyporesponsiveness induced by reactive oxygen species (ROS). Expand
The use of dendritic cells in cancer therapy.
TLDR
The biology of dendritic cells and their use in clinical trials are reviewed, as well as highlighting issues for future trial design. Expand
Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
TLDR
This review will focus on the T-cell co-stimulatory molecule CTLA4, which has entered clinical trials and demonstrated objective clinical responses, initially for metastatic melanoma and has been associated with organ-specific inflammatory adverse events. Expand
Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells
TLDR
It is demonstrated here that T-cell–specific blockade of TGF-β signaling allows the generation of an immune response capable of eradicating tumors in mice challenged with live tumor cells. Expand
T-cell-directed cancer vaccines: the melanoma model
TLDR
Using melanoma as the standard model for immunotherapy, various methods of T-cell-directed vaccination, the monitoring and analysis of the resulting immune response, and several clinical trials in which cancer vaccines have successfully induced immunisation are reviewed. Expand
Cancer immunoediting: from immunosurveillance to tumor escape
TLDR
The historical and experimental basis of cancer immunoediting is summarized and its dual roles in promoting host protection against cancer and facilitating tumor escape from immune destruction are discussed. Expand
Breaking tolerance in cancer immunotherapy: time to ACT.
TLDR
New insights from animal models and clinical trials suggest a rationale for combination approaches in which the ineffective endogenous anti-tumor immune response is enhanced through a combination of adoptive cell transfer (ACT), specific vaccination and cytokine help for the reliable induction of a robust anti- T-cell response and tumor regression. Expand
...
1
2
3
4
5
...